Alzchem Group AG Confirms Positive Growth in H1 2025

Alzchem Group AG continued its growth trajectory in the first half of 2025, as key financial indicators improved. With sales reaching EUR 287.6 million, the company slightly surpassed the previous year's level. EBITDA rose by 9% to EUR 56.5 million, resulting in a 19.6% EBITDA margin. Consolidated net income also increased by 14% to EUR 30.5 million.

Positive volume development in the Specialty Chemicals segment drove this success, with sales increasing by 9%. The segment's EBITDA grew by 18%, showing strong demand in Human Nutrition and Custom Manufacturing businesses. However, the Basics & Intermediates segment experienced a 14% decline in sales, influenced by external economic factors.

Alzchem's forecast for the full year remains optimistic with anticipated organic sales growth and increased EBITDA, highlighting a strategic focus on high-margin specialty chemicals.